Can sodium-glucose cotransporter 2 inhibitors 'spin the thread of life'?

Giuseppe Maltese1, Theocharis Koufakis2, Kalliopi Kotsa2

  • 1School of Cardiovascular Medicine and Sciences, King's College London, London, UK; Department of Diabetes and Endocrinology, Epsom and St Helier University Hospitals, Surrey, UK.

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer cardiovascular and renal benefits beyond glucose control. These SGLT2 inhibitors may promote longevity through anti-aging pathways, potentially involving soluble Klotho.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) initially developed for diabetes management.
  • Recent trials show SGLT2i reduce cardiovascular-renal events and mortality in diverse populations.
  • Observed benefits extend beyond glucose lowering, suggesting novel mechanisms.

Purpose of the Study:

  • To explore the anti-aging and pro-longevity effects of SGLT2 inhibitors.
  • To investigate the role of soluble Klotho in mediating SGLT2i's cardio-renal benefits.

Main Methods:

  • Review of randomized clinical trials and proposed mechanisms of action for SGLT2 inhibitors.
  • Analysis of signaling pathways, including Nrf2 activation and antioxidant enzyme induction.
  • Exploration of the association between SGLT2i and soluble Klotho levels.

Main Results:

  • SGLT2i demonstrate significant cardio-renal protective effects.
  • These benefits are independent of glycemic control.
  • Potential anti-aging effects mediated by pathways like Nrf2 and antioxidant enzymes.

Conclusions:

  • SGLT2 inhibitors possess pleiotropic effects contributing to cardiovascular and renal health.
  • Soluble Klotho may be a key mediator of SGLT2i's pro-longevity and cardio-renal protective actions.
  • SGLT2i represent a promising therapeutic target for age-related cardio-renal diseases.

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.6K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.1K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
266
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
237
Membrane Proteins01:30

Membrane Proteins

Plasma membranes have integral transmembrane proteins involved in facilitated transport. These proteins are collectively referred to as transport proteins, and they function as either channels for the material or as carriers themselves. Channel proteins have hydrophilic domains exposed to the intracellular and extracellular fluids and a hydrophilic channel through their core that provides a hydrated opening for solutes to pass through the membrane layers. Passage through the channel allows...
20.9K